Clinical trialNCT04279769CompletedPhase 1Interventional

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

SponsorCalithera Biosciences, IncEnrollment32Cystic Fibrosis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase 1b multiple ascending dose escalation study to evaluate the safety and tolerability of arginase inhibitor CB-280 in subjects with cystic fibrosis.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Emil T Kuriakose, MD
Calithera Bioscience
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

University of Calgary
Calgary, Alberta, Canada
St. Pauls' Hospital
Vancouver, British Columbia, Canada
Mcgill University Health Center
Montreal, Quebec, Canada

United States

University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Long Beach Memorial Medical Center
Long Beach, California, United States
University of Florida
Gainesville, Florida, United States
the Cystic Fibrosis Institute
Glenview, Illinois, United States
Indiana University
Indianapolis, Indiana, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Johns Hopkins University
Baltimore, Maryland, United States
Boston Children'S Hospital, Brigham & Women'S Hospital
Boston, Massachusetts, United States
Billings Clinic
Billings, Montana, United States
New York Medical College at Westchester Medical Center
Hawthorne, New York, United States
Unc Marsico Clinical Research Center
Chapel Hill, North Carolina, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Hershey Medical Center Pennsylvania State University
Hershey, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
University of Utah
Salt Lake City, Utah, United States
Vermont Lung Center at the University of Vermont Medical Center
Colchester, Vermont, United States
Virginia Commonwealth University
Richmond, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CB-280Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 3 Jul 2020
Primary completion: 23 Nov 2021
Completion: 23 Nov 2021
Last update posted: 13 Apr 2022
Registered enrollment: 32
Registry id: NCT04279769

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.